Search

Displaying results 7761 - 7770 of 10000 in total
  1. Drug

    Nisevokitug

    go.drugbank.com/drugs/DB17561
    Investigational

    Nisevokitug is a monoclonal antibody targeted against transforming growth factor beta (TGFβ) under investigation in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety

  2. Drug

    QL1706

    go.drugbank.com/drugs/DB17562
    Investigational

    QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.

  3. Drug

    Belvarafenib

    go.drugbank.com/drugs/DB17568
    Investigational

    Synonyms: 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno(3,2-d)pyrimidine-7-carboxamide, Thieno(3,2-d)pyrimidine-7-carboxamide, 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methyl-5-isoquinolinyl)-Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  4. Drug

    Crefmirlimab

    go.drugbank.com/drugs/DB17577
    Investigational

    Crefmirlimab is an anti-human CD8 probe targeting the CD8 antigen, for the diagnosis of various cancers.

    Synonyms: Iab22m2c (antibody fragment against the human cd8-antigen on cd8-positive t-cells)
  5. Drug

    DCVax-L

    go.drugbank.com/drugs/DB17580
    Investigational

    DCVax-L is a personalized immunotherapy comprising an autologous vaccine with dendritic cells loaded _in vitro_ with autologous tumour lysate.

    Synonyms: DCVax-L
  6. Drug

    Ad-CEA vaccine

    go.drugbank.com/drugs/DB17581
    Investigational

    Ad-CEA vaccine is a cancer immunotherapy composed of carcinoembryonic antigen (CEA). … Ad-CEA vaccine is under investigation in clinical trial NCT03050814 (Standard of Care Alone or in Combination With Ad-cea Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal

  7. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    [A257714] While effective, disease progression may occur 6 to 8 months after treatment with currently approved FGFR inhibitors is started, and this effect is usually associated with on-target resistance … KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs).

  8. Drug

    Loxoribine

    go.drugbank.com/drugs/DB17589
    Experimental

    Synonyms: 7-Allyl-7,8-dihydro-8-oxoguanosineCategories: Heterocyclic Compounds, 2-Ring
  9. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    [L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system. … [L54698] First approved by the FDA on December 9, 2025, etuvetidigene autotemcel is used to treat Wiskott–Aldrich syndrome (WAS) in selected pediatric and adult patients.

  10. Drug

    NP-6A4

    go.drugbank.com/drugs/DB17599
    Experimental

    NP-6A4 is a peptide designed to specifically bind and activate angiotensin II receptor type 2 (AT2R). It has an Orphan Drug designation from the FDA for pediatric cardiomyopathy.[A258523]